News · Approval
1,552 stories
Aug 12, 26STAT+: Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say
Aug 10, 26STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
Aug 10, 26STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more
Aug 10, 26Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies